Vivo Capital VIII, LLC - 21 Nov 2023 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Role
10%+ Owner
Signature
Vivo Capital VIII, LLC, By: /s/ Frank Kung, Managing Member
Issuer symbol
BOLT
Transactions as of
21 Nov 2023
Net transactions value
-$3,060
Form type
4
Filing time
22 Nov 2023, 18:51:43 UTC
Previous filing
20 Nov 2023
Next filing
19 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLT Common Stock Sale $1,536 -1,707 -0.09% $0.9000 1,952,302 21 Nov 2023 By: Vivo Capital Fund VIII, L.P. F1, F4
transaction BOLT Common Stock Sale $212 -236 -0.09% $0.9000 269,587 21 Nov 2023 By: Vivo Capital Surplus Fund VIII, L.P. F2, F4
transaction BOLT Common Stock Sale $1,311 -1,457 -1.3% $0.9000 111,662 21 Nov 2023 By: Vivo Opportunity Fund Holdings, L.P. F3, F4
holding BOLT Common Stock 1,448,286 21 Nov 2023 By: Vivo Panda Fund, L.P.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Vivo Capital VIII, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2 The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3 The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F4 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.